Clinical Trials Directory

Trials / Completed

CompletedNCT03401099

Cryoballoon Ablation as First Line Treatment of Atrial Flutter

Cryoballoon Pulmonary Vein Isolation as First Line Treatment for Typical Atrial Flutter

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
113 (actual)
Sponsor
Liverpool Heart and Chest Hospital NHS Foundation Trust · Academic / Other
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

Current guidelines recommend radiofrequency catheter ablation of the cavotricuspid isthmus as treatment for symptomatic/drug-refractory atrial flutter, in spite of the fact that recurrences of flutter and incidence of post-ablation atrial fibrillation are common. In this study, the investigators assess the hypothesis that the use of cryoballoon Pulmonary Vein Isolation ('novel' treatment) to achieve the electrical disconnection between the pulmonary veins and the heart will lead to higher rates of freedom from abnormal heart rhythms (atrial flutter, atrial fibrillation, or atrial tachycardia) and more improved quality of life than treatment using heat energy (radiofrequency ablation) directed at the cavotricuspid isthmus ('conventional treatment').

Detailed description

Atrial flutter and atrial fibrillation are believed to share the same initiating triggers in the form of pulmonary vein ectopy. Cavo-tricuspid isthmus-dependent atrial flutter almost always results from short bursts of antecedent atrial fibrillation. Radiofrequency (RF) ablation of the cavo-tricuspid isthmus (CTI) is the current accepted first-line treatment for atrial flutter, although post-ablation atrial fibrillation commonly occurs, even in the absence of pre-existing atrial fibrillation. Cryoballoon Pulmonary Vein Isolation (PVI) has become an established treatment for atrial fibrillation. In patients with both atrial flutter and fibrillation, PVI alone has been shown to control both types of atrial arrhythmia, with no benefit derived from supplemental RF CTI ablation. This study aims to demonstrate that standalone cryoballoon PVI for typical atrial flutter without RF CTI ablation will lead to a significant difference in preventing recurrence of atrial arrhythmia compared to radiofrequency ablation of the CTI, and should be offered as first-line therapy.

Conditions

Interventions

TypeNameDescription
PROCEDURERadiofrequency ablation of CTIDelivery of radiofrequency energy to the cavotricuspid isthmus (region of right atrial tissue between the tricuspid annulus and the inferior vena cava) until bidirectional block is achieved
PROCEDURECryoballoon PVICryoballoon application to the pulmonary veins aiming for Pulmonary Vein Isolation

Timeline

Start date
2018-08-17
Primary completion
2021-12-01
Completion
2023-11-01
First posted
2018-01-17
Last updated
2023-11-13

Locations

10 sites across 2 countries: Switzerland, United Kingdom

Source: ClinicalTrials.gov record NCT03401099. Inclusion in this directory is not an endorsement.